Evidence map›Paper›PMID 35590273›Full record

SynthesisBMC pediatrics2022

Efficacy and safety of sugammadex for neuromuscular blockade reversal in pediatric patients: an updated meta-analysis of randomized controlled trials with trial sequential analysis.

Bingchen Lang, Lu Han, Linan Zeng, Qianqian Zhang, Shouming Chen, Liang Huang, Zhijun Jia, Qin Yu, Lingli Zhang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Bradycardic Arrest in a Child with Complex Congenital Heart Disease Due to Sugammadex Administration.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Bingchen Lang *Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Lu Han *Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Linan ZengDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Qianqian ZhangDepartment of Anesthesiology, Chengdu Women's and Children's Central Hospital, Chengdu, China.
Shouming ChenKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.
Liang HuangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Zhijun JiaDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Qin YuKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China. 908929936@qq.com.
Lingli ZhangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. zhanglingli@scu.edu.cn.
Sichuan University · CNWest China Second University Hospital of Sichuan University · CNChengdu Women's and Children's Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA recent survey revealed that extensive off-label use of sugammadex in pediatric anesthesia deserved particular attention. The present study with trial sequential analysis (TSA) aimed to evaluate the effects of sugammadex for antagonizing neuromuscular blockade (NMB) in pediatric patients, and to investigate whether the findings achieved the required information size to draw conclusions.

methodsPubMed, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched from inception to April 2021. All randomized controlled trials used sugammadex as reversal agent in pediatric patients were enrolled. Time from NMB reversal to recovery of the train-of-four ratio (TOFr) to 0.9 and extubation time were considered as co-primary outcomes, and incidences of adverse events were considered as secondary outcomes. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to rate the quality of evidences.

resultsData from 18 studies involving 1,065 pediatric patients were acquired. The results revealed that use of sugammadex was associated with shorter duration from administration of reversal agents to TOFr > 0.9 (MD = -14.42, with 95% CI [-17.08, -11.75]) and shorter interval from reversal from NMB to extubation (MD = -13.98, with 95% CI [-16.70, -11.26]) compared to control groups. TSA also indicated that the current sample sizes were sufficient with unnecessary further trials. Analysis of secondary outcomes indicated that administration of sugammadex was associated with less incidence of postoperative nausea and vomiting (PONV), bradycardia, and dry mouth compared to control groups.

conclusionConsidering of satisfactory and rapid neuromuscular blockade reversal with low incidences of adverse events, sugammadex might be considered as the preferred option for children in clinical anesthesia practice compared to acetylcholinesterase inhibitors. However, overall low-quality evidences in present study rated by GRADE system indicated that superiority of sugammadex employed in pediatric patients needs to be confirmed by more studies with high quality and large sample size in future.

Indexed as

Neuromuscular BlockadeNeuromuscular Nondepolarizing AgentsSugammadexAcetylcholinesteraseChildHumansRandomized Controlled Trials as TopicAcetylcholinesteraseNeuromuscular Nondepolarizing AgentsSugammadexAcetylcholinesterase inhibitorsChildrenMeta-analysisNeuromuscular blockadeSugammadex

Identifiers

PMID35590273
PMCPMC9118813
OpenAlexW4280640178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.